Cargando…

MEDB-20. The outcome of medulloblastoma patients in the 2010-2018 period in Children’s Hospital Zagreb

This study aims to present the key characteristics of the medulloblastoma patients treated in Children’s Hospital Zagreb and the University Hospital Center Zagreb in Croatia between 2010-2018 period. Croatia has around 145 newly diagnosed pediatric oncology patients annually, including approximately...

Descripción completa

Detalles Bibliográficos
Autores principales: Jadrijevic-Cvrlje, Filip, Rajacic, Nada, Jednacak, Hrvoje, Grmoja, Tonci, Batos, Ana Tripalo, Gjurasin, Miroslav, Giljevic, Jasminka Stepan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164848/
http://dx.doi.org/10.1093/neuonc/noac079.394
_version_ 1784720241127849984
author Jadrijevic-Cvrlje, Filip
Rajacic, Nada
Jednacak, Hrvoje
Grmoja, Tonci
Batos, Ana Tripalo
Gjurasin, Miroslav
Giljevic, Jasminka Stepan
author_facet Jadrijevic-Cvrlje, Filip
Rajacic, Nada
Jednacak, Hrvoje
Grmoja, Tonci
Batos, Ana Tripalo
Gjurasin, Miroslav
Giljevic, Jasminka Stepan
author_sort Jadrijevic-Cvrlje, Filip
collection PubMed
description This study aims to present the key characteristics of the medulloblastoma patients treated in Children’s Hospital Zagreb and the University Hospital Center Zagreb in Croatia between 2010-2018 period. Croatia has around 145 newly diagnosed pediatric oncology patients annually, including approximately 30 neurooncology patients. We have conducted the retrospective analysis of the hospital records and have collected data on 32 medulloblastoma patients (9 females, 23 males). At the time of diagnosis, the median age was 5,62 (range 0.85-15.86). Before the treatment commencement, we determined conventional risk factors and stratified our patients into standard and high-risk groups (17 standard risk patients, 15 high risk). Qualification for high-risk included metastatic disease, postoperative local residual disease greater than 1.5 cm2, confirmed myc/nmyc amplification in the tumor tissue, and the large cell/anaplastic tumor subtype (p53 positive). The methods of molecular diagnostics were not available at the time. The patients that received solely postoperative chemotherapy were younger than three years. Children younger than five suffering from desmoplastic tumor subtype also received intraventricular methotrexate (Ommaya). High-dosage chemotherapy with autologous stem cell transplantation failed to treat metastatic infant medulloblastoma (2 patients with a lethal outcome). The rest of the patients received craniospinal irradiation, followed by adjuvant chemotherapy. According to the Kaplan-Meier survival analysis, the 5-year overall survival is 65,6 % (40% in the high-risk group and 88% in the standard-risk group). In addition, 5-year event-free survival is 59,4 % (33% in the high-risk group and 82,4% in the standard-risk group). None of the patients developed a secondary malignant disease during the follow-up. Conventional characteristics that determine standard-risk group affiliation are reliable, leading to a satisfactory treatment outcome. The results of the high-risk group treatment are poor necessitating modification treatment approach within clinical trials.
format Online
Article
Text
id pubmed-9164848
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91648482022-06-05 MEDB-20. The outcome of medulloblastoma patients in the 2010-2018 period in Children’s Hospital Zagreb Jadrijevic-Cvrlje, Filip Rajacic, Nada Jednacak, Hrvoje Grmoja, Tonci Batos, Ana Tripalo Gjurasin, Miroslav Giljevic, Jasminka Stepan Neuro Oncol Medulloblastoma This study aims to present the key characteristics of the medulloblastoma patients treated in Children’s Hospital Zagreb and the University Hospital Center Zagreb in Croatia between 2010-2018 period. Croatia has around 145 newly diagnosed pediatric oncology patients annually, including approximately 30 neurooncology patients. We have conducted the retrospective analysis of the hospital records and have collected data on 32 medulloblastoma patients (9 females, 23 males). At the time of diagnosis, the median age was 5,62 (range 0.85-15.86). Before the treatment commencement, we determined conventional risk factors and stratified our patients into standard and high-risk groups (17 standard risk patients, 15 high risk). Qualification for high-risk included metastatic disease, postoperative local residual disease greater than 1.5 cm2, confirmed myc/nmyc amplification in the tumor tissue, and the large cell/anaplastic tumor subtype (p53 positive). The methods of molecular diagnostics were not available at the time. The patients that received solely postoperative chemotherapy were younger than three years. Children younger than five suffering from desmoplastic tumor subtype also received intraventricular methotrexate (Ommaya). High-dosage chemotherapy with autologous stem cell transplantation failed to treat metastatic infant medulloblastoma (2 patients with a lethal outcome). The rest of the patients received craniospinal irradiation, followed by adjuvant chemotherapy. According to the Kaplan-Meier survival analysis, the 5-year overall survival is 65,6 % (40% in the high-risk group and 88% in the standard-risk group). In addition, 5-year event-free survival is 59,4 % (33% in the high-risk group and 82,4% in the standard-risk group). None of the patients developed a secondary malignant disease during the follow-up. Conventional characteristics that determine standard-risk group affiliation are reliable, leading to a satisfactory treatment outcome. The results of the high-risk group treatment are poor necessitating modification treatment approach within clinical trials. Oxford University Press 2022-06-03 /pmc/articles/PMC9164848/ http://dx.doi.org/10.1093/neuonc/noac079.394 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Medulloblastoma
Jadrijevic-Cvrlje, Filip
Rajacic, Nada
Jednacak, Hrvoje
Grmoja, Tonci
Batos, Ana Tripalo
Gjurasin, Miroslav
Giljevic, Jasminka Stepan
MEDB-20. The outcome of medulloblastoma patients in the 2010-2018 period in Children’s Hospital Zagreb
title MEDB-20. The outcome of medulloblastoma patients in the 2010-2018 period in Children’s Hospital Zagreb
title_full MEDB-20. The outcome of medulloblastoma patients in the 2010-2018 period in Children’s Hospital Zagreb
title_fullStr MEDB-20. The outcome of medulloblastoma patients in the 2010-2018 period in Children’s Hospital Zagreb
title_full_unstemmed MEDB-20. The outcome of medulloblastoma patients in the 2010-2018 period in Children’s Hospital Zagreb
title_short MEDB-20. The outcome of medulloblastoma patients in the 2010-2018 period in Children’s Hospital Zagreb
title_sort medb-20. the outcome of medulloblastoma patients in the 2010-2018 period in children’s hospital zagreb
topic Medulloblastoma
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164848/
http://dx.doi.org/10.1093/neuonc/noac079.394
work_keys_str_mv AT jadrijeviccvrljefilip medb20theoutcomeofmedulloblastomapatientsinthe20102018periodinchildrenshospitalzagreb
AT rajacicnada medb20theoutcomeofmedulloblastomapatientsinthe20102018periodinchildrenshospitalzagreb
AT jednacakhrvoje medb20theoutcomeofmedulloblastomapatientsinthe20102018periodinchildrenshospitalzagreb
AT grmojatonci medb20theoutcomeofmedulloblastomapatientsinthe20102018periodinchildrenshospitalzagreb
AT batosanatripalo medb20theoutcomeofmedulloblastomapatientsinthe20102018periodinchildrenshospitalzagreb
AT gjurasinmiroslav medb20theoutcomeofmedulloblastomapatientsinthe20102018periodinchildrenshospitalzagreb
AT giljevicjasminkastepan medb20theoutcomeofmedulloblastomapatientsinthe20102018periodinchildrenshospitalzagreb